Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise based in Melbourne, Australia, filed this Form 6-K for the month of August 2026. The report was signed by Chairman Julian Babarczy on August 28, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance rather than financial performance data.
Material Changes
No material changes versus a prior comparable period are disclosed in this filing. The document serves primarily to submit a Corporate Governance Statement as an exhibit.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The primary content is the submission of Exhibit 99.1, the Corporate Governance Statement, which is being incorporated by reference into various Registration Statements on Forms S-8 and F-3.
Investor Verification Checklist
- Verify the contents of the Corporate Governance Statement (Exhibit 99.1) referenced in this filing.
- Confirm the status of the Registration Statements on Forms S-8 and F-3 into which this report is incorporated.
- Review subsequent filings for financial data, as this specific 6-K does not contain quantitative financial metrics.